Safety of Secukinumab in Hepatitis B Virus

Abstract

The usage of TNF antagonists in patients with hepatitis B virus (HBV) can result in viral reactivation and potential liver failure. However, little is known about the risk of viral reactivation with the newer IL-17 antagonists. We report a patient with seropositive hepatitis B, ankylosing spondylitis, and disabling palmar plantar psoriasis treated successfully with secukinumab without liver complications.

This article is protected by copyright. All rights reserved.

http://ift.tt/2wXLJgA